Business
New to The Street TV / Newsmax TV announces its Eight Interviews for This Week’s TV Broadcast, Episode #290, January 16, 2022, 10-11 AM ET
New to The Street TV / Newsmax TV announces its Eight Interviews for This Week’s TV Broadcast, Episode #290, January 16, 2022, 10-11 AM ET.
About this update from Zerify Inc.
[{"type":"text","content":"\n NEW YORK, Jan. 14, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street / Newsmax TV announces the broadcasting line-up of its national syndicated 1- hour TV show this Sunday, January 16, 2022, airing time 10-11 AM ET. New to The Street’s 290th TV episode line-up, features eight interviews of the following Companies and their businesses representatives: 1). First Wave BioPharma, Inc.’s (NASDAQ: FWBI) interview, Mr. James Sapirstein, Chairman, CEO & President. 2). Cryptocurrency - Ariva, Inc.’s (CRYPTO: ARV) ($ARV), interview, Ms. Ashlee Stojanovski, Public Relations. 3). StrikeForce Technologies, Inc.’s (OTCQB: SFOR) interviews, Mr. Mark Kay, CEO, and Mr. George Waller, Executive Vice-President. 4). Pharmagreen Biotech, Inc.’s (OTCPINK: PHBI) interview, Mr. Peter Wojcik, CEO, and Ethan Styles, CEO, Long Valley Farms. 5). Cryptocurrency - Stacks’ (CRYPTO: STX) ($STX) interview, Dr. Muneeb Ali, Ph.D., Founder. 6). GlobeX Data Ltd.’s (OTCQB: SWISF) (CSE: SWIS) (FRA: GDT) interview, Mr. Alain Ghiai, CEO. 7). Cryptocurrency - Saitama, LLC’s (CRYPTO: SAITAMA) ($SAITAMA) interview, Mr. Russell Armand, COO. 8). Sekur’s® (a GlobeX Data, Ltd. division) “Weekly Hack - SPECIAL SEGMENT” interview, internet privacy expert Mr. Alain Ghiai, CEO. Returning this week, on New to The Street TV, Mr. James Sapirstein, Chief Executive Officer at First Wave BioPharma, Inc. (NASDAQ: FWBI) (formerly known as AzurRX Biopharma, Inc.), a clinical-stage biopharmaceutical Company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Mr. Sapirstein provides TV Anchor Jane King with a comprehensive update on current clinical trials in the USA and Europe. With 150+ people enrolled in a clinical trial on the gastrointestinal problems related to COVID-19, the Company expects in about 45-days those results on FW-COV. James talks about the current “Blind” trial ongoing in Italy, a study on ulcerated proctitis. This study uses the Company’s drug, FW-UP (niclosamide), preliminary data expected sometime in the 2nd quarter, 2022. Adrulipase, the Company’s drug used in several studies over the last seven years, James talks about the drug’s 2- trials performed in 2021, resulting in mixed results. He...